FDA accepts Antares Pharma Anturol Gel NDA
Anturol Gel, an oxybutynin gel incorporating Antares’ advanced transdermal delivery (ATD) Gel technology, is indicated for treatment in patients with overactive bladder (OAB). FDA is expected to complete
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.
The latest TEKLYNX innovation enables auditable tracking of user activity across TEKLYNX’ proven label design, printing, security and tracing applications. In addition to security measures, TEKLYNX CENTRAL CFR